We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Amphion Innovations Plc | LSE:AMP | London | Ordinary Share | GB00B0DJNP99 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.15 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From May 2019 to May 2024
TIDMAMP
RNS Number : 8947W
Amphion Innovations PLC
29 April 2016
Amphion Innovations plc
("Amphion" or "the Company")
Additional Terms on Loan Facility
London and New York, 29 April 2016 - On 28 April, Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, announced that the Company had agreed terms for the draw-down of an additional tranche of US $1,765,000 (an "Additional Draw") under the loan facility as announced on 5 June 2014 (the "Facility").
Additional terms of the Facility allow the conversion of the drawn-down amount into ordinary shares in Amphion ("Ordinary Shares"). Up to US $500,000 of the Facility may be converted at 6.5 pence per Ordinary Share and the remainder of the amount drawn-down under the Facility, approximately US $3.6 million, may be converted at 8.0 pence per Ordinary Share.
For further information please contact:
Amphion Innovations
Charlie Morgan
+1 212 210 6224
Yellow Jersey PR
Charles Goodwin / Dominic Barretto
+44 (0)7747 788 221
Panmure Gordon Limited (Nominated Adviser and Corporate Broker)
Freddy Crossley / Duncan Monteith (Corporate Finance)
Charlie Leigh-Pemberton (Corporate Broking)
+44 (0)20 7886 2500
Northland Capital Partners Limited (Joint Corporate Broker)
Patrick Claridge / David Hignell (Corporate Finance)
John Howes (Corporate Broking)
+44 (0)20 7382 1100
Plumtree Capital Limited (Financial Adviser)
Stephen Austin
+44 (0)20 7183 2493
+646 568 7502
About Amphion Innovations plc
Amphion Innovations is a developer of medical, life science and technology businesses.
We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in 7 Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies. The Partner Companies collectively own or control over 200 separately identified pieces of intellectual property, a number which grows rapidly each year.
On the web: www.amphionplc.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCAKCDKPBKDBQB
(END) Dow Jones Newswires
April 29, 2016 11:02 ET (15:02 GMT)
1 Year Amphion Innovations Chart |
1 Month Amphion Innovations Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
